This site is intended for healthcare professionals
News

CONSONANCE data of Ocrevus shows benefits in 1-year analysis with multiple sclerosis patients

Read time: 1 mins
Published:5th Apr 2022

Phase III CONSONANCE study data of Ocrevus shows benefits in 1-year analysis with multiple sclerosis patients.- Genentech/Roche

Genentech/Roche announced new phase III CONSONANCE study data with Ocrevus (ocrelizumab) that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS).

Treatment with Ocrevus resulted in a majority of patients experiencing no disease progression in a one-year analysis of CONSONANCE, a first-of-its-kind open-label Phase IIIb trial to evaluate the effect of Ocrevus in SPMS and PPMS patients. After one year, 75% of Ocrevus-treated patients with SPMS and PPMS achieved No Evidence of Progression (NEP; no evidence of confirmed disability progression as measured by an increase in Expanded Disability Status Score sustained for at least 24 weeks, and less than 20% worsening of performance on the timed 25-foot walk [T25-FW] and Nine-Hole Peg Test [9-HPT]). NEP is a novel composite endpoint and reflects no evidence of worsening of a person’s physical disability.

Additionally, 59% of Ocrevus-treated patients in the trial achieved No Evidence of Progression or Active Disease (NEPAD; NEP plus no protocol-defined relapses, new and/or enlarging T2 lesions or T1 gadolinium-enhancing lesions) over one year. The analysis also demonstrated the positive effects of Ocrevus on cognition, with 70% of patients having stable or improved cognition over one year, as measured with the Symbol Digit Modalities Test (SDMT). Clinically meaningful improvement (increase of at least 4 points on the SDMT) was observed in 34% of patients treated with Ocrevus and worsening (decrease of at least 4 points) in 30% of patients treated with Ocrevus. After one year of participating in the trial, 75% of patients had one or more adverse events (AEs) and 7% experienced at least one serious AE.

Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity will be a platform presentation at the 74th American Academy of Neurology (AAN) Annual Meeting April 2-7, 2022 in Seattle. CONSONANCE data will be presented virtually at AAN April 24-26, 2022.

Condition: Multiple Sclerosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.